Metx

ME Therapeutics Scientific and Corporate Update

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

ME Therapeutics Added to CSE25 Index

ME Therapeutics Secures U.S. Patent for Lead Candidate and Advances Broader Therapeutic Programs

ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease